Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

MSLP, LSTR, LCI, LTRX, CRWE - MusclePharm, Landstar Systems, Lannett, Lantronix, Crown Equity Holdings


Stock-PR Reporting



FREE Daily Stock Alerts From






Landstar System, Inc. (Nasdaq:LSTR)

LSTR reported net income in the 2010 third quarter of $21.8 million, or $0.44 per diluted share, on revenue of $623 million.  Under the terms of the purchase agreement by which the Company acquired National Logistics Management Co. (NLM) in July 2009, Landstar agreed to pay additional purchase price contingent upon the achievement by NLM of certain levels of earnings through 2014.

Landstar System, Inc. is a non-asset based provider of integrated supply chain solutions.


  MusclePharm Corporation (OTCQB:MSLP)

MSLP’s top management has extensive experience in the sports world and has harnessed this drive and focus into building a business to benefit its customers and help Fuel The Athlete Inside. MSLP is a fast-growing developer and manufacturer of safe, scientifically approved, nutritional supplements that are free of banned substances and tested by athletes. They are designed to help athletes, bodybuilders, weightlifters and fitness enthusiasts improve their performance. Each and every MSLP product is the end result of an advanced six-stage research and testing protocol involving the expertise of top nutrition scientists. In addition, the products have been field-tested by more than 100 elite professional athletes from the NFL, MMA, MLB and elsewhere. To date, MSLP has developed six products: ASSAULT, BATTLE FUEL, BULLET PROOF, COMBAT POWDER, RECON and SHRED MATRIX. Two additional products are due in stores in 2010. MSLP products offer up to twice as much of the active ingredients per serving as competing products and incorporate a proprietary mix of ingredients not available elsewhere. MSLP was founded in 2008 and is based in Aurora, Colorado.

MSLP announced last week that Ron Sekura, B.S., M.S., PhD., will join MSLP's board of directors as its Director of Therapeutic Research.

Dr. Sekura will be assisting in the development of MSLP's therapeutic indication and application for patients with HIV experiencing catabolic cachexia.

Dr. Sekura commented, "I am very pleased to join the board of MusclePharm as it expands into the field of therapeutic nutritional supplementation for the application of HIV disease. Catabolic cashexia is a wasting condition that is physically devastating and extremely costly to treat. There has not been a great deal of successful response with the current therapeutic options but I believe Musclepharm is properly focusing on solving this condition."

Ron Sekura is currently President of VivoNex LLC and Biotechnology Assessment Services, Inc. Dr. Sekura is the former Chief of the Pharmaceutical and Regulatory Affairs Branch of the Division of AIDS at The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institute of Health (NIH), as well as a former Research Chemist at The National Institute of Child Health and Human Development (NICHD) at the NIH and the Center for Biologics Evaluation and Research (CBER). He received his Bachelor of Science and Master of Science in Biochemistry degrees at Pennsylvania State University and his PhD at Cornell University. Dr. Sekura is the author of over sixty scientific publications.

MSLP's Recon Nutritional Supplement contains important amino acids, which assists in reaching the higher levels of nutrition required for people living with HIV. It is easily digestible, helps the absorption of amino acids and proteins. Recon contains essential minerals, digestive enzymes, Glutamine and other metabolic agents that maximize recovery, protein synthesis and endurance.

To learn more about MSLP visit:


Lannett Company, Inc. (AMEX:LCI)

LCI, a manufacturer of generic pharmaceuticals, released that it has commenced shipping Fluphenazine HCl Tablets USP, the generic equivalent of Prolixin®, in 1 mg, 2.5 mg, 5 mg and 10 mg dosages. For the 12 months ended September 2010, Fluphenazine HCl Tablets USP, 1 mg, 2.5 mg, 5 mg, & 10 mg had U.S. sales of approximately $28 million at Average Wholesale Price. Lannett acquired an FDA approved Abbreviated New Drug Application (NASDAQ:ANDA) for Fluphenazine HCl Tablets USP, in 1 mg, 2.5 mg, 5 mg and 10 mg dosages.

Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of indications.


Lantronix, Inc. (NASDAQ:LTRX)

LTRX, a leading provider of secure, remote management, device networking and data center management technologies, today announced it has filed a Schedule 14A in response to the filing of proxy solicitation materials from Mr. Bernhard Bruscha, owner of TL Investment GmbH. Mr. Bruscha is a non-independent member of the Lantronix Board of Directors and owns 38 percent of the outstanding shares of Lantronix.

Lantronix, Inc. is a global leader of secure communication technologies that simplify remote access, management and control of any electronic device.


  Crown Equity Holdings Inc. (OTCPK:CRWE)

CRWE is a consulting organization which provides and assists small business owners with the knowledge required in taking their company public, and has re-focused CRWE’s primary vision with its aligned group of independent website divisions to providing media advertising services, as a worldwide online media advertising publisher, dedicated to the distribution of quality branding information, as well as search engine optimization for its clients.

CRWE has recently launched its website to provide news in French and is launching CRWE’s Canadian website shortly. CRWE had previously launched its German website .

To learn more about CRWE visit:





Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings, Inc. (OTCPK:CRWE) has received twenty five thousand dollars in cash and seventy five thousand free trading shares from a third party (Bishop Equity Partners) for (30) days of advertising for Muscle Pharm Corp. (OTCQB:MSLP)

Sign Up For Free Stock Alerts At


Be Sure To Visit


The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.